These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Incidence of benign and malignant breast disorders in women taking hormones (contraceptive pill or hormonal replacement therapy).
    Author: Tzingounis V, Cardamakis E, Ginopoulos P, Argiropoulos G.
    Journal: Anticancer Res; 1996; 16(6C):3997-4000. PubMed ID: 9042326.
    Abstract:
    The incidence of breast disorders, in a series of 142 women of reproductive age who received combined oral contraception (OC) for birth control and in 98 postmenopausal women who received hormone replacement therapy (HRT) with estrogens and progestins, for seven years, was compared with control groups. A lower incidence of benign breast diseases was observed among OC users (p < 0.001) and HRT recipients (p < 0.001). No differences were observed in the incidence of breast cancer among the groups studied. OC use and HRT do not increase the risk for breast cancer and decrease the incidence of benign breast diseases. To assess the association between benign and malignant breast disease and hormone use, the incidence of such disorders was compared in 142 women (mean age, 29.9 years) who took combined oral contraceptives (OCs) for birth control and 98 postmenopausal women (mean age, 59.4 years) receiving hormone replacement therapy (HRT). The duration of use in both groups was 7 years. Women with a family history of breast cancer were excluded. Controls for OC users included 975 recruited from a family planning clinic; 323 women attending a menopause clinic served as controls for the HRT group. Participants received both mammography and/or breast ultrasound at baseline and at regular age-appropriate intervals. A statistically significant (p 0.001) difference between hormone users and controls was observed in the incidence of benign breast disease. There were 45 cases (31.69%) of benign breast disease among OC users compared with 536 (54.97%) among their controls and 19 such cases (19.88%) among HRT users compared with 121 (37.46%) among their controls. There was no observed breast cancer among women in either the OC or HRT group. These findings support the hypothesis that hormonal treatment has a beneficial effect on breast tissue and does not increase the risk of breast cancer.
    [Abstract] [Full Text] [Related] [New Search]